Control Charting Genomic Data
| Autor: | Midori Mitui, Jennifer Wagenfuehr, Khushbu Patel, Eric Londin, Jing Xu, Eric Crossley, Jason Y. Park |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Quality Control
0303 health sciences business.industry Clinical Laboratory Techniques Genomic data High-Throughput Nucleotide Sequencing General Medicine Computational biology Genomics Biology Reagent Lot Laboratory testing Deep sequencing 03 medical and health sciences 0302 clinical medicine 030220 oncology & carcinogenesis Humans Control chart Control material business Quality assurance 030304 developmental biology Retrospective Studies |
| Zdroj: | The journal of applied laboratory medicine. 6(4) |
| ISSN: | 2576-9456 |
| Popis: | Background Control charting is routine in the quality assurance of traditional clinical laboratory testing. Genomic tests are not typically managed by control charting. We examined control charting to monitor the performance of a clinical next-generation sequencing (NGS) assay. Methods We retrospectively examined 3 years of control material (NA12878) data from clinical genomic epilepsy testing. Levey-Jennings plots were used to visualize changes in control material depth of sequencing coverage in genomic regions of an epilepsy genomic panel. Changes in depth of coverage were correlated with changes in the manufactured lot of capture probe reagent. Depth of coverage was also correlated between quality control material and clinical samples. Results Fifty-seven sequencing runs of NA12878 were analyzed for 1811 genomic regions targeting 108 genes. Manufactured probe lot changes were associated with significant changes in the average coverage of 537 genomic regions and the lowest coverage of 173 regions (using a critical cut-off of P Conclusions Genomic control charting can be used routinely by clinical laboratories to monitor assay performance and ensure the quality of testing. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|